LONDON (Reuters) – AstraZeneca Chief Executive Pascal Soriot said on Friday the company is “very encouraged” by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as “clinically meaningful”.
The drugmaker’s shares fell by as much as 8% earlier this month, after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan.
At the time, investors were disappointed the company did not say the data was “clinically meaningful”, a potential suggestion that the benefits may not be as pronounced as hoped.
He was speaking to media after the company released better-than-expected quarterly results.
(Reporting by Maggie Fick and Josephine Mason; editing by David Evans)
